Applied Genetic Technologies Corporation AGTC
Set alert
0.39 0.00 0.00%
At close · Nov 30
0.37 Day range 0.40
52-week range unavailable
- Open
- 0.37
- Prev close
- 0.3936
- Mkt cap
- 0
- Vol
- 764.53K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.37
- High
- 0.40
- Forward P/E
- -0.27
- Beta
- 1.58
- Short ratio
- 0.65
- Inst. own
- 29.93%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 6, 2022
- 50-d avg
- 0.34974
- 200-d avg
- 0.665742
- 1y target
- 0.34
Analyst view
Consensus: hold
Hold
Price target (mean) 0.34
Ratings (0m) 6 3 buy · 3 hold · 0 sell
- Strong buy1
- Buy2
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
- 3 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.36 | -0.39 – -0.34 | -0.45 | +20.0% | 0 | 0.0% | 2 |
| Next quarter | -0.21 | -0.39 – -0.04 | -0.33 | +36.4% | 0 | 0.0% | 2 |
| Current year | -0.87 | -1.48 – -0.26 | -1.53 | +43.1% | 0 | 0.0% | 2 |
| Next year | -1.47 | -1.47 – -1.47 | -0.87 | -69.0% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 25, 2022 | Wells Fargo | Maintained | — | Equal-Weight |
| Oct 25, 2022 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Oct 24, 2022 | Wedbush | Downgrade | Outperform | Neutral |
| Oct 24, 2022 | Stifel | Downgrade | Buy | Hold |
| Oct 4, 2022 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Sep 30, 2022 | Stifel | Maintained | — | Buy |
| Sep 30, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 29, 2022 | BTIG | Downgrade | Buy | Neutral |
| Sep 28, 2022 | Chardan Capital | Maintained | — | Buy |
| May 18, 2022 | Chardan Capital | Maintained | — | Buy |
| Jun 15, 2021 | BTIG | Initiated | — | Buy |
| Mar 2, 2021 | Stifel | Initiated | — | Buy |
| Feb 1, 2021 | Roth Capital | Maintained | — | Buy |
| Nov 17, 2020 | Roth Capital | Maintained | — | Buy |
| Nov 11, 2020 | Berenberg | Initiated | — | Buy |
| Jun 23, 2020 | Cantor Fitzgerald | Initiated | — | Overweight |
| Jan 28, 2020 | Roth Capital | Initiated | — | Buy |
| Sep 27, 2019 | Wedbush | Maintained | — | Outperform |
| Sep 27, 2019 | BMO Capital | Upgrade | Market Perform | Outperform |
| Sep 6, 2019 | Janney Capital | Initiated | — | Buy |
| Sep 3, 2019 | Chardan Capital | Upgrade | Neutral | Buy |
| Dec 13, 2018 | BMO Capital | Downgrade | Outperform | Market Perform |
| Sep 24, 2018 | Wells Fargo | Upgrade | Market Perform | Outperform |
| Sep 11, 2018 | Chardan Capital | Downgrade | Buy | Neutral |
| Sep 14, 2017 | BMO Capital | Maintained | — | Outperform |
| Sep 14, 2017 | Cantor Fitzgerald | Maintained | — | Neutral |
| Mar 15, 2017 | Rodman & Renshaw | Initiated | — | Buy |
| Nov 9, 2016 | Roth Capital | Upgrade | Neutral | Buy |
| Sep 26, 2016 | Janney Capital | Upgrade | Sell | Neutral |
| Sep 13, 2016 | Roth Capital | Downgrade | Buy | Neutral |